- Disease
- Wednesday, 09 Oct 2019
Prevail's new AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
Prevail's new AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, and Lonza recently, announced that the companies have entered into a strategic collaboration.
Lonza and Prevail have been working together since 2018, with an initial focus on process development, towards the GMP manufacturing of Prevail's two lead programs, PR001 and PR006. Under this collaboration, focused on the baculovirus/Sf9 production system for gene therapies, Lonza will manufacture Prevail's pipeline of novel AAV-based gene therapy programs for patients with neurodegenerative diseases at its gene therapy center of excellence in Houston, TX.
Prevail's pipeline includes PR001, an AAV9-based gene therapy delivering GBA1, in development for Parkinson’s disease patients with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease patients (nGD). Prevail plans to initiate a Phase 1/2 clinical trial of PR001 in PD-GBA in 2019. The company is also developing PR006, an AAV9-based gene therapy delivering GRN, for frontotemporal dementia patients with a GRN mutation (FTD-GRN). Prevail anticipates PR006 will enter the clinic in 2020. The collaboration also has the potential to extend to Prevail's future pipeline of AAV-based gene therapy programs.
Prevail has built in-house process and analytical development capabilities utilizing both HEK293 and baculovirus/Sf9 AAV expression systems. Under this collaboration, Prevail and Lonza will work closely together on process development, analytical development, and large-scale production using the baculovirus/Sf9 process for late-stage clinical and commercial supply at Lonza’s GMP facility in Houston.
Related Industry Updates
Shockwaves to Global Economy with Rising Coronavirus Crisis in World's Manufacturing Hub
Jan 27, 2020
Coronavirus on G20 agenda as China reports uptick in cases
Feb 21, 2020
COVID-19 Crisis will Push Automation in Several Industries
May 25, 2020
Facebook, Google recommended their San Francisco Bay Employees to work from home as coronavirus spreads
Mar 06, 2020
Coronavirus in China Sent a Ripple of Risk Aversion Through Markets
Jan 21, 2020
Goldman Sachs sees 1 percent drop in global GDP owing to 'coronacrisis'
Mar 23, 2020
Japan will sell record amount of extra bonds to combat coronavirus crisis
Apr 07, 2020